SIDE EFFECTS OF INTRAVENOUS GANCICLOVIR AND COMBINATION OF INTRAVENOUS GANCICLOVIR-ORAL VALGANCICLOVIR IN PEDIATRIC PATIENTS WITH CYTOMEGALOVIRUS INFECTION
Objective: Intravenous ganciclovir and oral valganciclovir are known to have severe side effects against hematopoiesis and kidney function. This study aims to look for these side effects in pediatric patients with cytomegalovirus (CMV) infection treated with ganciclovir or a combination regimen of both in Hasan Sadikin General Hospital, a tertiary care center in West Java, Indonesia.
Methods: This was a cross-sectional study using medical records and laboratory examination data from pediatric patients with CMV infection who received ganciclovir of 6 mg/kg twice a day, valganciclovir of 16 mg/kg twice a day, or a combination of both in Hasan Sadikin General Hospital from January 2015 to January 2019. Differences before and after therapy were analyzed to look for any side effects in each regimen and duration of therapy.
Results: Out of 115 patients, there were 53 subjects who met the research criteria. Majority of the subjects used a combination regimen (n=29, 55%) for 6 weeks (n=36, 68%). There was no statistically significant difference (p>0.05) in the incidence of anemia, neutropenia, thrombocytopenia, increase in creatinine serum, or increase in blood urea nitrogen for different regimen or duration of therapy.
Conclusion: No side effects were found to be related with therapeutic regimen or duration of therapy in pediatric patients with CMV infection in this study.
2. Na SY. Cytomegalovirus infection in infantile hepatitis. Pediatr Gastroenterol Hepatol Nutr 2012;15:91-9.
3. Swanson EC, Schleiss MR. Congenital cytomegalovirus infection: New prospects for prevention and therapy. Pediatr Clin North Am 2013;60:1-17.
4. McMullan BJ, Palasanthiran P, Jones CA, Hall BM, Robertson PW, Howard J, et al. Congenital cytomegalovirus time to diagnosis, management and clinical sequelae in Australia: Opportunities for earlier identification. Med J Aust 2011;194:625-9.
5. Somaji L, Rapolu R. Binding studies of valganciclovir to human serum albumin by multispectroscopic techniques. Int J Pharm Pharm Sci 2018;10:87-92.
6. Kliegman R, Stanton B, Schor N. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA: Elsevier; 2016.
7. Kadambari S, Williams EJ, Luck S, Griffiths PD, Sharland M. Evidence based management guidelines for the detection and treatment of congenital CMV. Early Hum Dev 2011;87:1-6.
8. Patel R, Patel G, Gajra B, Parikh R. Formulation of optimization and characterization of ganciclovir loaded dry chitosan nanoparticles. Asian J Pharm Clin Res 2017;10:295-9.
9. Kimberlin D, Jester P, Sanchez, Ahmed A, Boger R, Michaels N. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015;372:933-43.
10. Napoleon AA, Angajala G, Kumar R. Novel synthesis of process related impurities of valganciclovir hydrochloride. Int J Pharm Pharm Sci 2016;8:29-31.
11. Ozkan T, Mistik R, Dikici B, Nazlioglu H. Antiviral therapy in neonatal cholestatic cytomegalovirus hepatitis. BMC Gastroenterol 2007;7:1-5.
12. Asberga A, Humar A, Rollagc H, Jardined AG, Mouase H, Pescovitz MD, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007;7:2106-13.
13. Asberg A, Humar A, Rollag H, Jardine A, Kumar D, Aukrust P, et al. Lessons learned from a randomized study of oral valganciclovir versus parenteral ganciclovir treatment of cytomegalovirus disease in solid organ transplant recipients: The victor trial. Clin Infect Dis 2016;1:1154-60.
14. Gandhi R, Fernandez-Alvarez JR. Management of congenital cytomegalovirus infection: An evidence-based approach. Acta Pediatr 2010;99:509-15.
15. Bilavsky E, Schwarz M, Bar-Sever Z, Pardo J, Amir J. Hepatic involvement in congenital cytomegalovirus infection-infrequent yet significant. J Viral Hepat 2014;22:1-6.
16. Doan TT, Phung TT, Pham HV, Pham SH, Nguyen LT. Effect of ganciclovir for the treatment of severe cytomegalovirus-associated pneumonia in children without a specific immunocompromised state. BMC Infect Dis 2013;13:424.
17. Rosal TD, Baquero-Artigao F, Blázquez D, Noguera-Julian A, Moreno-Pérez D, Reyes A, et al. Treatment of symptomatic congenital cytomegalovirus infection beyond the neonatal period. J Clin Virol 2012;55:72-4.
18. Prasetyo D. Update Diagnostik Dan Tatalaksana Ikterik Pada Bayi. Pediatric Update 2015. Bandung: Fakultas Kedokteran Universitas Padjadjaran; 2015.
19. Amita D, Balaji O, Patil N. Valganciclovir-induced thrombocytopenia: A case report. Asian J Pharm Clin Res 2017;10:3-4.
20. Young S, Azzam RK. Infantile cholestasis approach and diagnostic algorithm. In: Guandalini, Dhawan A, Branski D, editors. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition. Switzerland: Springer Inc.; 2016. p. 625-31.
21. Glaser SS, Gaudio E, Miller T, Alvaro D, Alpini G. Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med 2009;25:e7.
22. Plosa EJ, Esbenshade JC, Fuller MP, Weitkamp JH. Cytomegalovirus Infection. Pediatr Rev 2012;33:155-63.
23. Buonsenso DS, Gargiullo L, Ceccarelli M, Ranno O, Valentini P. Congenital cytomegalovirus infection: Current strategies and future perspectives. Eur Rev Med Pharmacol Sci 2012;16:919-35.
24. Matsumoto K, Shigemi A, Ikawa K, Kanazawa N, Fujisaki Y, Morikawa N, et al. Risk factors for ganciclovir-induced thrombocytopenia and leukopenia. Biol Pharm Bull 2015;38:235-8.
25. Tezer H, Secmeer G, Kara A, Ceyhan M, Cengiz AB, Devrim I, et al. Cytomegalovirus hepatitis and ganciclovir treatment in immunocompetent children. Turk J Pediatr 2008;50:228-34.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.